-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Truist Securities Downgrades Fate Therapeutics to Hold, Lowers Price Target to $7

Benzinga · 01/06/2023 05:01
Truist Securities analyst Robyn Karnauskas downgrades Fate Therapeutics (NASDAQ:FATE) from Buy to Hold and lowers the price target from $46 to $7.